A non-functional galanin receptor-2 in a multiple sclerosis patient.
Journal
The pharmacogenomics journal
ISSN: 1473-1150
Titre abrégé: Pharmacogenomics J
Pays: United States
ID NLM: 101083949
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
received:
26
11
2017
accepted:
14
05
2018
revised:
26
04
2018
pubmed:
23
8
2018
medline:
21
3
2019
entrez:
23
8
2018
Statut:
ppublish
Résumé
Multiple Sclerosis (MS) is an inflammatory neurodegenerative disease that affects approximately 2.5 million people globally. Even though the etiology of MS remains unknown, it is accepted that it involves a combination of genetic alterations and environmental factors. Here, after performing whole exome sequencing, we found a MS patient harboring a rare and homozygous single nucleotide variant (SNV; rs61745847) of the G-protein coupled receptor (GPCR) galanin-receptor 2 (GALR2) that alters an important amino acid in the TM6 molecular toggle switch region (W249L). Nuclear magnetic resonance imaging showed that the hypothalamus (an area rich in GALR2) of this patient exhibited an important volumetric reduction leading to an enlarged third ventricle. Ex vivo experiments with patient-derived blood cells (AKT phosphorylation), as well as studies in recombinant cell lines expressing the human GALR2 (calcium mobilization and NFAT mediated gene transcription), showed that galanin (GAL) was unable to stimulate cell signaling in cells expressing the variant GALR2 allele. Live cell confocal microscopy showed that the GALR2 mutant receptor was primarily localized to intracellular endosomes. We conclude that the W249L SNV is likely to abrogate GAL-mediated signaling through GALR2 due to the spontaneous internalization of this receptor in this patient. Although this homozygous SNV was rare in our MS cohort (1:262 cases), our findings raise the potential importance of impaired neuroregenerative pathways in the pathogenesis of MS, warrant future studies into the relevance of the GAL/GALR2 axis in MS and further suggest the activation of GALR2 as a potential therapeutic route for this disease.
Identifiants
pubmed: 30131588
doi: 10.1038/s41397-018-0032-6
pii: 10.1038/s41397-018-0032-6
doi:
Substances chimiques
Receptor, Galanin, Type 2
0
Galanin
88813-36-9
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
72-82Subventions
Organisme : Ministry of Science, Technology and Innovation | Conselho Nacional de Desenvolvimento Científico e Tecnológico (National Council for Scientific and Technological Development)
ID : 480138/2013-3
Pays : International
Organisme : Fundação de Amparo à Pesquisa do Estado de São Paulo (São Paulo Research Foundation)
ID : 2015/07925-5
Pays : International
Organisme : Fundação de Amparo à Pesquisa do Estado de São Paulo (São Paulo Research Foundation)
ID : 2016/06488-3
Pays : International
Organisme : Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (Brazilian Federal Agency for the Support and Evaluation of Graduate Education)
ID : 23038.007775/2014-98
Pays : International
Organisme : Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (Brazilian Federal Agency for the Support and Evaluation of Graduate Education)
ID : 7350-15-5
Pays : International